AuthorisedPhase I and Phase II (Integrated)- OtherInterventional

IL-1β blockade to prevent Immunothrombosis in recipients of a Pancreatic Organ (ILIPO)

This research study, called ILIPO, is for adults with diabetes who are having a pancreas transplant. Pancreas transplants can be life-changing, but sometimes serious problems like infections or the body rejecting the new organ can occur. This study aims to see if a medication called Kineret, given along with other standard treatments, can help prevent these complications. Researchers will carefully watch how patients recover over the first year, looking at things like the number of infections, how well the new pancreas is working, and if transplant rejection happens. They'll compare this to a group of similar patients who had transplants in the past to understand if the new approach is helpful.

At a glance

Status

Authorised

Phase

Phase I and Phase II (Integrated)- Other

Sponsor

Centre Hospitalier Universitaire De Nantes

Enrolment target

Start

12 Mar 2026

diabetic patients pancreatic transplant

What is this study about?

If you have diabetes and are considering a pancreas transplant, this study might be of interest. A pancreas transplant can be a fantastic way to manage diabetes, but like any major operation, it comes with potential challenges. Sometimes, the body's immune system can try to reject the new pancreas, or patients can get serious infections because their immune system is working hard to accept the new organ.

This study, called ILIPO, is looking into a new way to help prevent these problems. It's investigating whether giving a medicine called Kineret, alongside the usual medications, can make a difference. Kineret works by blocking a specific part of the immune system that might be involved in rejection or causing clots that can harm the new pancreas.

The main goal is to see if patients receiving Kineret have fewer serious infections, less organ rejection, and a better chance of their new pancreas working well for at least a year after the transplant. The doctors will compare the health of patients in this study to those who've had pancreas transplants in the past, to understand the potential benefits of this new approach.

Key takeaways

This study is testing a new way to prevent problems after a pancreas transplant.
It involves a medicine called Kineret, given alongside usual treatments.
Researchers will monitor for serious infections, organ rejection, and overall recovery for one year.
The goal is to improve the success and safety of pancreas transplants for people with diabetes.
It's an early-stage study looking for promising results.

Who may be eligible?

This study is for adult patients who are 18 years old or older and are planning to have a pancreas transplant. It doesn't matter if you are male or female, as long as you meet the other requirements.

To be considered for this study, you must be a diabetic patient who is going to receive a pancreas transplant. The doctors will need to check your full medical history to make sure that taking part in the study would be safe and appropriate for you.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years old or older?
Are you a diabetic patient?
Are you going to receive a pancreas transplant?
Are you willing to potentially take a new medication alongside your usual treatments?

Answer every question to see your result.

What does participation involve?

If you join this study, you will receive the study medication, Kineret, in addition to the standard treatments you would normally get after a pancreas transplant. You will have regular check-ups and tests, likely including blood tests, to monitor your health, how the new pancreas is working, and to watch for any side effects or infections. You'll also be carefully monitored for any signs of the body rejecting the transplant, which might involve a biopsy (taking a small tissue sample) if needed. These assessments will continue for about one year after your pancreas transplant to see the full effects of the study treatment.

Potential risks and benefits

Taking part in this study could potentially offer a benefit by reducing the chance of serious infections or rejection of your new pancreas. However, all medications have potential side effects, and Kineret might have its own risks, which your doctors will discuss with you. There's also the chance that the treatment might not work as expected. You are free to withdraw from the study at any time, for any reason, without it affecting your standard medical care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

—
Unverified
France

Common questions

What is a Phase I/II study?

This means it's an early-stage study that combines two phases. Phase I checks if the treatment is safe, and Phase II sees how well it works and finds the best dose. It's about gathering initial information.

What is Kineret?

Kineret is a medication that helps control part of your body's immune system. In this study, it's being tested to see if it can help prevent problems after a pancreas transplant.

What does 'immunothrombosis' mean?

It's a medical term for when your immune system accidentally causes blood clots. The study hopes Kineret might stop this from happening after a transplant, protecting your new pancreas.

Will I still get my usual medicines?

Yes, you will receive Kineret alongside the standard medications typically given after a pancreas transplant. It's an additional treatment being tested.

What is 'graft survival'?

This refers to how long your transplanted pancreas continues to work well in your body. The study hopes to improve this by preventing complications.